Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Shares Issued (2016 - 2025)

Ligand Pharmaceuticals' Shares Issued history spans 16 years, with the latest figure at $29.2 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 838.49% year-over-year to $29.2 million; the TTM value through Dec 2025 reached $44.8 million, up 20.51%, while the annual FY2025 figure was $67.4 million, 81.45% up from the prior year.
  • Shares Issued for Q4 2025 was $29.2 million at Ligand Pharmaceuticals, up from $8.2 million in the prior quarter.
  • Across five years, Shares Issued topped out at $29.2 million in Q4 2025 and bottomed at -$12.5 million in Q3 2023.
  • The 5-year median for Shares Issued is $3.8 million (2023), against an average of $6.3 million.
  • The largest annual shift saw Shares Issued soared 6192.87% in 2021 before it plummeted 1628.66% in 2023.
  • A 5-year view of Shares Issued shows it stood at $4.3 million in 2021, then tumbled by 142.79% to -$1.8 million in 2022, then plummeted by 584.6% to -$12.5 million in 2023, then surged by 124.81% to $3.1 million in 2024, then surged by 838.49% to $29.2 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Shares Issued are $29.2 million (Q4 2025), $8.2 million (Q2 2025), and $4.2 million (Q1 2025).